Elixir Ai
Entrepreneur First '17London, GB · Founded 2017 · 1 known investors
Elixir AI makes software for running paediatric clinical trials, covering protocol authoring, digital recruitment and consent, remote data capture through online forms, and automated analysis of collected data. It is aimed at paediatricians and clinical researchers, with the goal of reducing the administrative work involved in a trial and shortening study timelines.
Also known as Elixir AI
Founders & leadership
Elixir Ai was founded in 2017 by Ed Cartwright and Agne Kazakeviciute.
Investors · 1
Company profile
researched Aug 2026Elixir AI is a London-based software company, founded in 2017, focused on the operation of paediatric clinical trials. Its platform is intended to cover the trial lifecycle: authoring tools for protocol creation, digital recruitment and electronic consent, remote data capture via online forms, and automated analysis of the data collected. The stated aim is to cut the administrative workload associated with running a study and to shorten trial timelines.
No additional public reporting about this company was found among the source documents supplied. The searched material instead concerns unrelated entities that share the Elixir name — a wellness/"digital self" venture, a Solana-based token project for AI 3D-asset generation, a French light-aircraft manufacturer, and an India-based geospatial analytics firm — none of which relate to the paediatric clinical-trial software company covered here. Consequently, funding, traction, customer and headcount information could not be corroborated from the public sources available.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
Positioned within clinical trial technology, with a narrow focus on paediatric studies rather than general-purpose eClinical software. Public sources do not establish market share, customers or competitive standing.
Technology
Software platform combining protocol authoring tools, digital recruitment and consent workflows, remote electronic data capture through online forms, and AI-assisted analysis of trial data.
Go-to-market
Paediatricians and clinical researchers conducting trials in child health.
Geography
Headquartered in London, United Kingdom. No further locations are evidenced by available sources.
Risks & controversies
The company name overlaps with several unrelated organisations using the Elixir or Elixir AI name, which complicates public identification and verification. Publicly available documentation on the company itself is extremely limited, so funding status, commercial traction and current operating status remain unverified externally.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
▸Research sources · 6
primary sources listed
- ELIXIR AIelixirforever.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Elixir Ai do?
- Elixir AI builds software to design, run and analyse paediatric clinical trials, reducing administrative burden for researchers.
- Who founded Elixir Ai?
- Elixir Ai was founded by Ed Cartwright, Agne Kazakeviciute in 2017.
- Who are Elixir Ai's investors?
- Elixir Ai's investors include Entrepreneur First.
- Where is Elixir Ai headquartered?
- Elixir Ai is headquartered in London, GB.